Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692106 | 1.00 | ADORA3 (0.74) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL28120773 | 0.92 | KDM4E (0.64) | ADORA3ADORA1KDM4EPKMADORA2A | |
| Adenosine SCHEMBL28274972 | 0.91 | ADORA3 (0.68) | ADORA3ADORA1ADORA2AADORA2BMAPK1 | |
| SCHEMBL21685900 | 0.90 | ADORA3 (0.61) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL8818470 | 0.88 | KDM4E (0.59) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL28952609 | 0.88 | KDM4E (0.59) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL8818497 | 0.88 | KDM4E (0.59) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL29278767 | 0.87 | ADORA3 (0.59) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL18171845 | 0.86 | KDM4E (0.57) | ADORA3ADORA1KDM4EPKMADORA2A | |
| SCHEMBL18371513 | 0.86 | KDM4E (0.57) | ADORA3ADORA1KDM4EPKMADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2655 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4632075-A2 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-10-15 | — | — | EP | claimed |
| US-20250304965-A1 | DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-10-02 | — | — | US | claimed |
| EP-4029522-B1 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| CN-117866948-B | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240366793-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | CALIFORNIA INST OF TECHN (US) | 2024-11-07 | — | — | US | claimed |
| EP-3656872-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2020-05-27 | — | — | EP | claimed |
| CN-110870871-A | Methods and pharmaceutical compositions for treating cancer | 澳门科技大学 | 2020-03-10 | — | — | CN | claimed |
| US-20200071695-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | INCREASEPHARM (HK) LIMITED (HK) | 2020-03-05 | — | — | US | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-3387150-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2018-10-17 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| WO-2017098468-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| WO-2014039809-A2 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-03-13 | — | — | WO | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |